Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

FDA Drug Recalls

18,003 recalls, newest first

Class II · Moderate risk

Ibuprofen Oral Suspension USP

Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

Terminated Particulate / foreign matter Taro Pharmaceuticals U.S.A., Inc. NDC 51672-1385-9 D-0299-2020
Class II · Moderate risk

Ibuprofen Oral Suspension USP

Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

Terminated Particulate / foreign matter Taro Pharmaceuticals U.S.A., Inc. NDC 51672-1385-8 D-0298-2020
Class III · Low risk

Testosterone Cypionate Injection

Labeling:Label Mix-up: Shipper Carton labelled Testosterone Cypionate Injection, USP, 200mg/mL, 1 ml single-dose vials, found to contain shelf cartons labelled as Testosterone Cypionate Injection USP, 200mg/mL, 10 ml multi-dose vials which contain Testosterone Cypionate Injection USP, 200mg/mL,1mL single-does vials

Terminated Labeling / mix-up Arbor Pharmaceuticals Inc. NDC 52536-625-01 D-0167-2020
Class II · Moderate risk

Estradiol tablets

Presence of Foreign Tablets/Capsules: Estradiol 1 mg was found in a 100 count bottle of Estradiol 0.5 mg Tablets.

Terminated Particulate / foreign matter Epic Pharma, LLC NDC 42806-087-01 D-0135-2020
Class III · Low risk

Benazepril HCl Tablets

Presence of Foreign Tablet/Capsule; Promethazine HCl tablet found in the Benazepril HCl bottle

Terminated Particulate / foreign matter Amneal Pharmaceuticals, Inc. NDC 65162-754-10 D-0134-2020
Class III · Low risk

Ranitidine Tablets USP

CGMP DEVIATIONS: One lot of Ranitidine Tablets USP, 150 mg is being recalled because some bottles were empty.

Ongoing cGMP deviation AuroMedics Pharma LLC NDC 55910-092-79 D-0166-2020
Class II · Moderate risk

Dextroamphetamine Sacharate

Superpotent Drug: Amphetamine Mixed Salts 20mg have been found to be out of specification for weight and thickness.

Terminated Wrong potency / content Aurobindo Pharma USA Inc. NDC 13107-073-01 D-0143-2020
Class II · Moderate risk

Losartan Potassium/ Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0124-2020
Class II · Moderate risk

Losartan Potassium /Hydrochlorothiazide Tablets

CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level of 9.82 parts per million.

Ongoing Nitrosamine impurity Torrent Pharma Inc. D-0123-2020

Recalls by year